glp 1 agonist crohn's disease GLP-1 based therapies and course of inflammatory bowel disease Glucagon-like peptide-1 receptor agonists in

We hypothesize that the influence of SFN on the gut microbiota is at least partly related to the effects on their habitat, i.e., the gut such as (i) alleviation of oxidative stress and inflammation in the intestine, (ii) increase of the expression of tight junction proteins, preventing excessive intestinal permeability and invasion of luminal bacteria, and (iii) promotion of gut detoxification capability via increase of activity of phase II detoxification enzymes such as GSTs

It's a start, but we really need formalized approaches based on clinical outcomes to drive this feel forward

Confirm both statements below to access the catalog

doi:10.1186/1471-2377-9-s1-s2 19

He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, et al